Stock
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) CANF
Overview
CANF market data
Price History
CANF price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CANF. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in OncologyGlobenewswire Inc · Jul 20, 2026, 12:02 PM
Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The EventBenzinga · Jul 20, 2026, 11:16 AM
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque PsoriasisBenzinga · Jul 6, 2026, 11:10 AM
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8Benzinga · Jul 2, 2026, 11:05 AM
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer PatientsBenzinga · Jul 1, 2026, 2:15 PM
Market-Moving News for July 1stBenzinga · Jul 1, 2026, 11:25 AM
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 MonthsBenzinga · Jul 1, 2026, 11:10 AM
Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug CaseBenzinga · Jun 26, 2026, 2:15 PM
Market-Moving News for June 26thBenzinga · Jun 26, 2026, 11:30 AM
Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity ActivityBenzinga · Jun 26, 2026, 11:10 AM